Results 171 to 180 of about 4,164 (194)
Some of the next articles are maybe not open access.
Romosozumab for the treatment of osteoporosis
Expert Opinion on Biological Therapy, 2017Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD ...
Leonardo, Bandeira +2 more
openaire +2 more sources
Romosozumab — Promising or Practice Changing?
New England Journal of Medicine, 2017Over the past decade, the osteoporosis landscape has changed. Even though more treatment options are available, fewer measurements of bone mass are being performed and fewer prescriptions for antiosteoporosis agents are being written — the last probably related to concerns about known side effects of bisphosphonates, such as atypical femoral fractures ...
openaire +2 more sources
Romosozumab Treatment in Postmenopausal Osteoporosis
New England Journal of Medicine, 2017Felicia, Cosman +2 more
openaire +6 more sources
Romosozumab-aqqg, upadacitinib, and risankizumab-rzaa
Journal of the American Pharmacists Association, 2019Daniel A, Hussar, Haley E, Helms
openaire +2 more sources